The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Enhancing the efficacy of immunotherapies in pancreatic cancer with BXCL701
Despite immunotherapies having a positive impact in many types of cancer, they have not been as successful in pancreatic cancer, where chemotherapy remains the standard of care. There are only a few targetable mutations and a dense fibroblastic tumor stroma often surrounds the tumor. Benjamin Adam Weinberg, MD, FACP, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, comments how BXCL701 can improve the efficacy of immunotherapies such as pembrolizumab in pancreatic cancer. BXCL701 increases inflammasome activity and enables immunotherapies to penetrate the tumor. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Employment – Apple (I)
Stock and Other Ownership Interests – Apple (I)
Honoraria – Primum
Consulting or Advisory Role – AstraZeneca/Daiichi Sankyo; Bayer; DoMore Diagnostics; Foundation Medicine; Merus NV
Speakers’ Bureau – Bayer; Daiichi Sankyo/Astra Zeneca; Merus NV; Natera; Seagen; Sirtex Medical; Taiho Pharmaceutical
Research Funding – Abbvie (Inst); BioXCel therapeutics (Inst); Immune System Key (Inst); Ipsen (Inst); Merck (Inst)
Expert Testimony – AstraZeneca
Travel, Accommodations, Expenses – Merus NV
